Oral Erosive Lichen Planus Treated With Efalizumab

Cheng, Amy; Mann, Caroline

doi:10.1001/archderm.142.6.680

Cited by 48 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently an approved drug for the treatment of plaque psoriasis. [26] Figure 1 gives a schematic representation of the probable sites of action of drugs based on their property in OLP.…”

Section: Other Immunosuppressants and Immunomodulatory Agentsmentioning

confidence: 99%

Oral lichen planus: An update on pathogenesis and treatment

Lavanya

Jayanthi

Rao

et al. 2011

J Oral Maxillofac Pathol

269

215

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucus membrane of the oral cavity. It is a T-cell mediated autoimmune disease in which the cytotoxic CD8+ T cells trigger apoptosis of the basal cells of the oral epithelium. Several antigen-specific and nonspecific inflammatory mechanisms have been put forward to explain the accumulation and homing of CD8+ T cells subepithelially and the subsequent keratinocyte apoptosis. A wide spectrum of treatment modalities is available, from topical corticosteroids to laser ablation of the lesion. In this review, we discuss the various concepts in the pathogenesis and current treatment modalities of OLP.

show abstract

Section: Other Immunosuppressants and Immunomodulatory Agentsmentioning

confidence: 99%

Oral lichen planus: An update on pathogenesis and treatment

Lavanya

Jayanthi

Rao

et al. 2011

J Oral Maxillofac Pathol

269

215

View full text Add to dashboard Cite

show abstract

“…The dosage of efalizumab was 0.7 mg /kg -1 mg/kg/week for 3-10 weeks and dosage of alefacept was 15 mg/week IM for 12 weeks. [36,37] Efalizumab can cause subacute cutaneous lupus erythematosus, for which it has been withdrawn. The efficacy of these agents could be possibly attributed to their mechanism of action; efalizumab interacts with the leukocytefunction antigen-1 (LFA-1), whereas alefacept interacts with LFA-3.…”

Section: Uvb Phototherapymentioning

confidence: 99%

A Systematic Review of Management of Oral Lichen Planus

Jena¹,

Das²

2016

jemds

View full text Add to dashboard Cite

Oral Lichen Planus (OLP) is a relatively common chronic inflammatory disorder with a low risk of associated malignancy. A genetic predisposition linked to Th1 cytokine polymorphisms may predispose to the T-cell-mediated immunological response to an induced antigenic change that is supposed to cause OLP lesions. Topical immunomodulators such as corticosteroids and calcineurin inhibitors may control OLP lesions, but their long-term effects need to be better explored and understood. A systematic review of published data on oral lichen planus is presented with special reference to its treatment modalities. Typically, different medical and surgical modalities and newer therapeutic options are considered that contribute to symptomatic relief and palliative functional improvement to the patients. Eventually, the magnitude of the illness as a pre-malignant disease in a considerable size of patients signifies the need for promising treatment options.

show abstract

“…There is one report of a patient with refractory oral and cutaneous lichen planus who experienced significant improvement after treatment with efalizumab. 305 Oral disease was reduced by approximately 75%, and most cutaneous lesions involuted to hyperpigmented macules by 10 weeks.…”

Section: Efalizumabmentioning

confidence: 99%